ERBB2 and B-cell non-Hodgkin lymphoma: This hypothesis spurred research that has led to the identification of overexpressed antigens like human epidermal growth factor receptor 2 (HER2) in breast cancer and cluster of differentiation 20 (CD20) in B-cell lymphoma, enabling targeted cancer therapy using monoclonal antibodies (mAbs) [12].